emjreviews.com4d
Deep Learning Tool Predicts Immunotherapy Efficacy in Lung Cancer
A deep learning radiomic biomarker has been developed and validated to predict responses to immune checkpoint inhibitors in ...
STAT8d
With promising early data in triple negative breast cancer, a new bispecific heats up
New data suggests researchers may have found one of their most promising candidates yet for the next generation in ...
labiotech8d
Targeting sugar molecules: Can glycobiology lead to a new era for cancer immunotherapy?
Find out more about the emerging field of glycobiology, which could potentially lead to a new type of cancer immunotherapy.
The American Journal of Managed Care2d
Top 5 Most-Read ALL/AML Articles in 2024
New treatments and adverse events impacting patient quality of life were among the topics of interest in 2024.
emjreviews.com12d
Higher Thromboembolic Risk in Patients with Lung Cancer on Immunotherapy
A recent study highlights an increased risk of thromboembolic events in metastatic lung cancer patients treated with immune ...
TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc.
TuHURA Biosciences, Inc. (Nasdaq: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies ...
Future Market Insights1d
Global Next Generation Immunotherapies Market to reach USD 268.84 billion by 2033, Monoclonal Antibodies were Primary Drug Class: FMI Report
Immunotherapies have become a cornerstone in cancer treatment, with current therapies like checkpoint inhibitors enhancing ...
Medscape1d
Atezolizumab Plus Neoadjuvant Chemotherapy Fails to Meet Primary Endpoint in Early-Stage TNBC
The addition of atezolizumab to neoadjuvant chemotherapy failed to significantly improve event-free survival in patients with ...